Tagged with BI

cardiology The general manager of Argentia weighs up the factors that have led to his company consolidating its different business lines and becoming one of the fastest growing companies in Argentina.   What was your main objective upon joining Argentia? In 1995, Argentia was acquired by BMS and was sold to…

innovation Hugo Sigman explains how understanding problems in the same way as opportunities helped his company to become what is today, a successful Argentinian conglomerate where life and science is the backbone of multiple businesses.   Please start by describing the Insud group as it stands today, and where it operates.…

biotech Bioceres manages investments in agricultural biotechnology and related sciences. The company’s CEO, Federico Trucco, discusses the potential of Argentina’s biotech scene to become a world-class drug developer in biopharma as well as Bioceres’ own investments in the sector.   How did you become involved with Bioceres? I have known the…

chamber of commerce MGCC’s Executive Director discusses the opportunities and challenges for German pharma and healthcare companies to invest in Malaysia, at a time where most have decided to invest and base their headquarters in Singapore.     Could you please start by introducing what are the main tasks and objectives of the…

generics Chile is aiming to achieve complete bioequivalence of generics by the end of 2014. Chile’s Public Health Institute is leading the bioequivalence testing, aimed at regulating differences between generic and bioequivalent drugs. The recently appointed director of the Public Health Institute, Ricardo Fabrega, echoes the need for drastic change and…

biotech For many years, Spain’s biotechnology sector was lagging behind the powerhouses of countries like the US and UK. Today, the sector touts a significantly different story, due to strategic investments by Spain’s government. Regina Revilla, president of Spain’s biotech association ASEBIO, details the history of biotech in Spain and outlines…

amgen Roland Wandeler, general manager of Amgen Iberia, discusses the affiliate’s commitment to innovation, clinical trials, and the importance of providing both medicines and solutions in order to foster a more sustainable health ecosystem for the future of Spain. You became general manager of Amgen Iberia in 2012, in the middle…

amgen Roland Wandeler, general manager of Amgen Iberia, discusses the affiliate’s commitment to innovation, clinical trials, and the importance of providing both medicines and solutions in order to foster a more sustainable health ecosystem for the future of Spain. You became general manager of Amgen Iberia in 2012, in the middle…

Indian When Indian generics company Aurobindo established itself in Portugal in 2010, the affiliate was faced with some difficult choices. As the latest company to enter the Portuguese generic market, Aurobindo had the lowest prices in the market, which was not attractive to the pharmacy channel. Pedro Merlini, country manager of…

Cell2B David Malta and Daniela Couto, Co-founders of Cell2B, discuss the company’s origins and plans to achieve market authorization, and what makes the fledgling company the partner of choice.   What do you see as Portugal’s capacity for the local life sciences industry to grow? DM: Portugal is one of the best-positioned…

diagnostics Life Length was founded through the CNIO (Spanish National Cancer Research Center) combined with the support of the Botín Foundation, Matlin Associates and Dr. Maria Blasco’s work in telomeres. Stephen J. Matlin, CEO of Life Length, discusses the potential of the company’s diagnostic test to become a standard biomarker for…

Biosano “A company active in the Chilean pharmaceutical market has to reinvent its business model every three years because today we are competing against some of the largest multinationals.”     How has the company developed over the past years? Chile has a very open and transparent market, which requires companies to…